Literature DB >> 7509144

Viral resistance to the thiazolo-iso-indolinones, a new class of nonnucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase.

G Maass1, U Immendoerfer, B Koenig, U Leser, B Mueller, R Goody, E Pfaff.   

Abstract

Thiazolo-iso-indolinone derivatives with high specificity toward the reverse transcriptase (RT) of human immunodeficiency virus type 1 (HIV-1) were identified. The most potent compound, BM +51.0836, inhibited HIV-1 RT at a 50% inhibitory concentration of 90 nM in vitro. In cell culture assays, similar 50% inhibitory concentrations were obtained with high specificity for HIV-1. These substances were equally active against a zidovudine-resistant isolate. No antiviral effect was observed with an HIV-2 isolate. HIV-1 isolates resistant to the thiazolo-iso-indolinones were generated in cell culture, and the nucleotide sequences of the respective RT genes were analyzed subsequently. Comparison of the deduced amino acid sequences with the wild-type sequence showed an amino acid change at position 181 (Tyr to Cys). Substitutions of amino acid Lys-101 and Lys-103 as well as Tyr-181 and/or Tyr-188 by site-directed mutagenesis led to resistance against the thiazolo-iso-indolinones. A chimeric HIV-2 RT, substituted with amino acids at positions 179 to 190 from HIV-1, acquired only partial susceptibility to BM +51.0836.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7509144      PMCID: PMC192754          DOI: 10.1128/AAC.37.12.2612

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  19 in total

Review 1.  HIV-1 reverse transcriptase: structure predictions for the polymerase domain.

Authors:  A M Barber; A Hizi; J V Maizel; S H Hughes
Journal:  AIDS Res Hum Retroviruses       Date:  1990-09       Impact factor: 2.205

2.  HIV-1-specific reverse transcriptase inhibitors show differential activity against HIV-1 mutant strains containing different amino acid substitutions in the reverse transcriptase.

Authors:  J Balzarini; A Karlsson; M J Pérez-Pérez; L Vrang; J Walbers; H Zhang; B Oberg; A M Vandamme; M J Camarasa; E De Clercq
Journal:  Virology       Date:  1993-01       Impact factor: 3.616

3.  Infection of HTLV-III/LAV in HTLV-I-carrying cells MT-2 and MT-4 and application in a plaque assay.

Authors:  S Harada; Y Koyanagi; N Yamamoto
Journal:  Science       Date:  1985-08-09       Impact factor: 47.728

4.  Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds.

Authors:  R Pauwels; J Balzarini; M Baba; R Snoeck; D Schols; P Herdewijn; J Desmyter; E De Clercq
Journal:  J Virol Methods       Date:  1988-08       Impact factor: 2.014

5.  Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives.

Authors:  R Pauwels; K Andries; J Desmyter; D Schols; M J Kukla; H J Breslin; A Raeymaeckers; J Van Gelder; R Woestenborghs; J Heykants
Journal:  Nature       Date:  1990-02-01       Impact factor: 49.962

6.  Co-expression of the subunits of the heterodimer of HIV-1 reverse transcriptase in Escherichia coli.

Authors:  B Müller; T Restle; S Weiss; M Gautel; G Sczakiel; R S Goody
Journal:  J Biol Chem       Date:  1989-08-25       Impact factor: 5.157

7.  Viral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors.

Authors:  J H Nunberg; W A Schleif; E J Boots; J A O'Brien; J C Quintero; J M Hoffman; E A Emini; M E Goldman
Journal:  J Virol       Date:  1991-09       Impact factor: 5.103

8.  Expression of the heterodimeric form of human immunodeficiency virus type 2 reverse transcriptase in Escherichia coli and characterization of the enzyme.

Authors:  B Müller; T Restle; H Kühnel; R S Goody
Journal:  J Biol Chem       Date:  1991-08-05       Impact factor: 5.157

9.  Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor.

Authors:  V J Merluzzi; K D Hargrave; M Labadia; K Grozinger; M Skoog; J C Wu; C K Shih; K Eckner; S Hattox; J Adams
Journal:  Science       Date:  1990-12-07       Impact factor: 47.728

10.  DNA sequencing with chain-terminating inhibitors.

Authors:  F Sanger; S Nicklen; A R Coulson
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

View more
  5 in total

Review 1.  Antiviral therapy for human immunodeficiency virus infections.

Authors:  E De Clercq
Journal:  Clin Microbiol Rev       Date:  1995-04       Impact factor: 26.132

2.  Highly potent oxathiin carboxanilide derivatives with efficacy against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus isolates.

Authors:  R W Buckheit; M J Snow; V Fliakas-Boltz; T L Kinjerski; J D Russell; L A Pallansch; W G Brouwer; S S Yang
Journal:  Antimicrob Agents Chemother       Date:  1997-04       Impact factor: 5.191

3.  Anti-human immunodeficiency virus (HIV) activities of halogenated gomisin J derivatives, new nonnucleoside inhibitors of HIV type 1 reverse transcriptase.

Authors:  T Fujihashi; H Hara; T Sakata; K Mori; H Higuchi; A Tanaka; H Kaji; A Kaji
Journal:  Antimicrob Agents Chemother       Date:  1995-09       Impact factor: 5.191

4.  Synthesis of Schiff bases of naphtha[1,2-d]thiazol-2-amine and metal complexes of 2-(2'-hydroxy)benzylideneaminonaphthothiazole as potential antimicrobial agents.

Authors:  Faizul Azam; Satendra Singh; Sukhbir Lal Khokhra; Om Prakash
Journal:  J Zhejiang Univ Sci B       Date:  2007-06       Impact factor: 3.066

5.  Structure-activity and cross-resistance evaluations of a series of human immunodeficiency virus type-1-specific compounds related to oxathiin carboxanilide.

Authors:  R W Buckheit; T L Kinjerski; V Fliakas-Boltz; J D Russell; T L Stup; L A Pallansch; W G Brouwer; D C Dao; W A Harrison; R J Schultz
Journal:  Antimicrob Agents Chemother       Date:  1995-12       Impact factor: 5.191

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.